Systemic Administration of IL-15 Augments the Antigen-Specific Primary CD8+ T Cell Response Following Vaccination with Peptide-Pulsed Dendritic Cells

• DOI: 10.4049/jimmunol.169.9.4928
• Publication Date: 2014-04-21T00:57:06Z
• Authors: Mark P. Rubinstein; Andre N. Kadima; Mohamed L. Salem; Christophe L. Nguyen; William E. Gillan...; David J. Cole
• Keywords: Cytotoxicity, Immunologic; Interleukin-15; 0301 basic medicine; Cell Death; Egg Proteins; Epitopes, T-Lymphocyte; Cell Differentiation; Mice, Transgenic; Dendritic Cells; CD8-Positive T-Lymphocytes; Lymphocyte Activation; Adoptive Transfer; Immunophenotyping; 3. Good health; Mice, Inbred C57BL; Mice; 03 medical and health sciences; Adjuvants, Immunologic; Injections, Intravenous; Animals; Humans; Immunologic Memory; Injections, Intraperitoneal

The systemic administration of IL-2 can act as a potent adjuvant for T cell-directed vaccine strategies. However, not only is the potentially toxic, but recent evidence suggests that it may also paradoxically limit duration and magnitude cytotoxic cell response. A recently identified cytokine, IL-15, shares many properties with provide preferential means augmenting responses. Although well characterized in vitro, there are few data on ability IL-15 to augment cell-mediated responses vivo. We therefore evaluated function murine model. To establish population easily identifiable Ag-responsive cells, naive CD8(+) (OT-1) cells were first adoptively transferred into mice. Vaccination peptide-pulsed dendritic induced modest expansion OT-1 cells. addition 7 days following vaccination resulted significant increase responding PBL, spleen, lymph nodes. Importantly, maintained Tc1-biased phenotype. did observe either enhanced resistance activation-induced death or generation memory result treatment compared IL-2. These studies show time capable primary response contribute basis future experiments exploring clinical role IL-15.